Cognition Therapeutics Inc (CGTX) concluded trading on Wednesday at a closing price of $0.58, with 288.38 million shares of worth about $167.26 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -71.57% during that period and on December 18, 2024 the price saw a gain of about 27.50%. Currently the company’s common shares owned by public are about 40.81M shares, out of which, 35.21M shares are available for trading.
Stock saw a price change of 19.29% in past 5 days and over the past one month there was a price change of 25.35%. Year-to-date (YTD), CGTX shares are showing a performance of -68.65% which decreased to -65.88% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.34 but also hit the highest price of $2.95 during that period. The average intraday trading volume for Cognition Therapeutics Inc shares is 1.54 million. The stock is currently trading 32.76% above its 20-day simple moving average (SMA20), while that difference is up 23.47% for SMA50 and it goes to -53.50% lower than SMA200.
Cognition Therapeutics Inc (NASDAQ: CGTX) currently have 40.81M outstanding shares and institutions hold larger chunk of about 10.36% of that.
The stock has a current market capitalization of $24.10M and its 3Y-monthly beta is at 1.24. It has posted earnings per share of -$0.96 in the same period. It has Quick Ratio of 2.11 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CGTX, volatility over the week remained 34.79% while standing at 16.03% over the month.
Stock’s fiscal year EPS is expected to drop by -0.78% while it is estimated to increase by 13.00% in next year.
Coverage by Oppenheimer stated Cognition Therapeutics Inc (CGTX) stock as an Outperform in their note to investors on November 03, 2021, suggesting a price target of $22 for the stock.
